Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

H Bischoff; MC Garassino; J Mazieres; M Reck; C Chouaid; L Cove-Smith; T Mansy; MR Migliorino; A Delmonte; JG Sanchez; LEC Velarde; R Bernabe; L Paz-Ares; ID Perez; N Trunova; K Foroutanpour; C Faivre-Finn; N Reinmuth

Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

H Bischoff, MC Garassino, J Mazieres, M Reck, C Chouaid, L Cove-Smith, T Mansy, MR Migliorino, A Delmonte, JG Sanchez, LEC Velarde, R Bernabe, L Paz-Ares, ID Perez, N Trunova, K Foroutanpour, C Faivre-Finn, N Reinmuth

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	160-161
Number of pages	2
Journal	Oncology Research and Treatment
Volume	45
Issue number	SUPPL 3
Publication status	Published - Nov 2022

Cite this

Bischoff, H., Garassino, MC., Mazieres, J., Reck, M., Chouaid, C., Cove-Smith, L., Mansy, T., Migliorino, MR., Delmonte, A., Sanchez, JG., Velarde, LEC., Bernabe, R., Paz-Ares, L., Perez, ID., Trunova, N., Foroutanpour, K., Faivre-Finn, C., & Reinmuth, N. (2022). Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Oncology Research and Treatment, 45(SUPPL 3), 160-161.

@article{31048e4dc5144d0b973054f56d083a4a,

title = "Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)",

author = "H Bischoff and MC Garassino and J Mazieres and M Reck and C Chouaid and L Cove-Smith and T Mansy and MR Migliorino and A Delmonte and JG Sanchez and LEC Velarde and R Bernabe and L Paz-Ares and ID Perez and N Trunova and K Foroutanpour and C Faivre-Finn and N Reinmuth",

year = "2022",

month = nov,

language = "English",

volume = "45",

pages = "160--161",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "SUPPL 3",

}

Bischoff, H, Garassino, MC, Mazieres, J, Reck, M, Chouaid, C, Cove-Smith, L, Mansy, T, Migliorino, MR, Delmonte, A, Sanchez, JG, Velarde, LEC, Bernabe, R, Paz-Ares, L, Perez, ID, Trunova, N, Foroutanpour, K, Faivre-Finn, C & Reinmuth, N 2022, 'Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)', Oncology Research and Treatment, vol. 45, no. SUPPL 3, pp. 160-161.

TY - JOUR

T1 - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

AU - Bischoff, H

AU - Garassino, MC

AU - Mazieres, J

AU - Reck, M

AU - Chouaid, C

AU - Cove-Smith, L

AU - Mansy, T

AU - Migliorino, MR

AU - Delmonte, A

AU - Sanchez, JG

AU - Velarde, LEC

AU - Bernabe, R

AU - Paz-Ares, L

AU - Perez, ID

AU - Trunova, N

AU - Foroutanpour, K

AU - Faivre-Finn, C

AU - Reinmuth, N

PY - 2022/11

Y1 - 2022/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000883051700375&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 2296-5270

VL - 45

SP - 160

EP - 161

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 3

ER -

Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

Other files and links

Cite this